Auréa Group Invests in Premium Haircare Brands, Zenagen and ACT/IV

London, 9 January 2025: The Auréa Group (“Auréa”), a specialist private equity firm focused on beauty, wellness and longevity, today announced its investment in Nutraceutical Research Innovations (“NRI”), the owner of premium haircare brands, Zenagen and ACT/IV.

NRI’s cutting-edge plant-based solutions align with the rising demand in the prestige haircare market, complementing Auréa’s expanding portfolio of beauty brands, which includes The Body Shop. This marks Auréa’s second investment in haircare, alongside Scandinavian Biolabs, and its second US-based brand.

Founded in 2008, Zenagen is a premium professional haircare brand offering plant-based products designed to treat fine and thinning hair. Zenagen has established itself as a trusted solution across professional channels, including salons, spas, dermatology clinics, and aestheticians. With Auréa’s support, Zenagen will continue to strengthen its presence in professional markets while expanding into direct-to-consumer platforms such as Amazon.

ACT/IV, founded in 2016, is a lifestyle haircare brand with a strong foothold in professional beauty channels, including nationwide distribution. With a focus on innovation and accessibility, ACT/IV will prioritize digital growth while exploring opportunities for further retail expansion.

Paul Raphael, Auréa’s co-founding partner commented: “Zenagen and ACT/IV are outstanding brands that deliver proven, effective solutions for their customers. With increasing consumer demand for premium, purpose-driven haircare products, NRI is exceptionally well-positioned to thrive. We look forward to bringing Auréa’s operational experience and unparalleled network in working with the team to unlock the brands’ next phase of growth.”

A spokesperson for NRI, said: “We chose The Auréa Group as our partner because of their unmatched combination of industry expertise and capabilities- from scaling digital engagement and e-commerce to optimizing global operations. We are looking forward to working with them on Zenagen and ACT/IV’s growth journey.”